Kairos Ventures
Early-stage venture investor that backs inventions, patents and companies spun out from universities and academic labs. The firm describes its focus as investing in ideas, patents and businesses from top universities and scientists and supporting entrepreneurs and scientists to move technologies from the lab to the boardroom.
Industries
Nr. of Employees
medium (51-250)
Kairos Ventures
Beverly Hills, California, United States, North America
Portfolio
Portfolio company developing AuriNovo™, a patient-specific 3D-bioprinted living tissue ear implant. Reported milestones include Orphan Drug designation (Nov 19, 2019), FDA Rare Pediatric Disease designation (Dec 6, 2019), and a Phase 1/2a first-in-human ear reconstruction procedure and clinical trial (June 2022).
#Regenerative medicine; 3D-bioprinting; biologics/therapeutic implants
Uses medicinal chemistry technology from Caltech and biomarker-driven assays from UCLA to accelerate pre-clinical drug discovery and clinical timelines. Year founded 2017. CEO: David Licata. Board observer: Paul Becker.
#Pharma; pre-clinical drug discovery
Portfolio company developing AuriNovo™, a patient-specific 3D-bioprinted living tissue ear implant. Reported milestones include Orphan Drug designation (Nov 19, 2019), FDA Rare Pediatric Disease designation (Dec 6, 2019), and a Phase 1/2a first-in-human ear reconstruction procedure and clinical trial (June 2022).
#Regenerative medicine; 3D-bioprinting; biologics/therapeutic implants
Uses medicinal chemistry technology from Caltech and biomarker-driven assays from UCLA to accelerate pre-clinical drug discovery and clinical timelines. Year founded 2017. CEO: David Licata. Board observer: Paul Becker.
#Pharma; pre-clinical drug discovery